Phase 2 Lymphoma Trial, Recruiting (NCT06758037)

Phase 2 Lymphoma Trial, Recruiting NCT06758037 Sponsor: First Affiliated Hospital of Ningbo University Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06758037 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 70 years of age or older
Your general health and ability to carry out daily activities falls within a certain range, from fully active to limited self-care (confirm with trial site)
A simplified geriatric (older adult) health assessment has rated you as "unfit" or "frail"
You have been diagnosed through a biopsy with a specific type of blood cancer called CD20-positive diffuse large B-cell lymphoma (DLBCL), confirmed under a microscope, but not a specific transformed subtype (confirm with trial site)
You have been newly diagnosed and have not yet received any treatment for this condition
Your kidneys, liver, and heart are functioning within acceptable levels based on blood test results (confirm with trial site)
You have at least one area of cancer that can be measured on a scan
You are either unable to tolerate the standard chemotherapy treatment (called CHOP) or you do not wish to receive chemotherapy
You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

The cancer has spread to your brain or spinal cord
You have a known HIV infection
You are pregnant or currently breastfeeding
You have another type of cancer that currently requires treatment
You have an active infection that is not under control
You have active hepatitis B, and the virus levels in your blood cannot be kept low enough even with antiviral medication (confirm with trial site)
You are unable to understand or follow the study rules, or you are unable to sign the consent form

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06758037

Sponsor: First Affiliated Hospital of Ningbo University

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

More information: https://clinicaltrials.gov/study/NCT06758037

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 70 years of age or older
Your general health and ability to carry out daily activities falls within a certain range, from fully active to limited self-care (confirm with trial site)
A simplified geriatric (older adult) health assessment has rated you as "unfit" or "frail"
You have been diagnosed through a biopsy with a specific type of blood cancer called CD20-positive diffuse large B-cell lymphoma (DLBCL), confirmed under a microscope, but not a specific transformed subtype (confirm with trial site)
You have been newly diagnosed and have not yet received any treatment for this condition
Your kidneys, liver, and heart are functioning within acceptable levels based on blood test results (confirm with trial site)
You have at least one area of cancer that can be measured on a scan
You are either unable to tolerate the standard chemotherapy treatment (called CHOP) or you do not wish to receive chemotherapy
You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

The cancer has spread to your brain or spinal cord
You have a known HIV infection
You are pregnant or currently breastfeeding
You have another type of cancer that currently requires treatment
You have an active infection that is not under control
You have active hepatitis B, and the virus levels in your blood cannot be kept low enough even with antiviral medication (confirm with trial site)
You are unable to understand or follow the study rules, or you are unable to sign the consent form

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

First Affiliated Hospital of Ningbo University

Registry

ClinicalTrials.gov

Start date

15 January 2025

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate (CR) at the end of 6 cycles

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov